Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature

Overview

Journal Drug Saf Case Rep

Date 2016 Oct 18

PMID 27747682

Citations 13

Authors

Zhuying Cai

Wei Yang

Yingying He

Qingge Chen

Shiqiang Wang

Xuming Luo

Xiongbiao Wang

Affiliations

Soon will be listed here.

Abstract

An 87-year-old woman developed abdominal wall hematoma and upper gastrointestinal bleeding during treatment with cefoperazone/sulbactam for pneumonia. The woman received cefoperazone/sulbactam at 4.5 g twice daily for intravenous infusion. After 7 days, she developed sudden onset of left lower abdominal pain, associated with subcutaneous mass, and vomited a coffee-colored liquid. Investigations revealed a coagulation index abnormality and activated partial thromboplastin time and prothrombin time increased obviously. She was diagnosed with cefoperazone-induced hemorrhage. Cefoperazone/sulbactam was discontinued and the patient received vitamin K1. The blood coagulation function improved and hematoma disappeared after 3 days. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's coagulation function disorder and her use of the suspect drug.

Citing Articles

The clinical features and risk factors of coagulopathy associated with cefoperazone/sulbactam: a nomogram prediction model.

Xu C, Zhu J, Tu K, Tang H, Zhou X, Li Q Front Pharmacol. 2025; 15():1505653.

PMID: 39830359 PMC: 11742127. DOI: 10.3389/fphar.2024.1505653.

Cefoperazone-Sulbactam-Induced Coagulopathy in Critically Ill Egyptian Patients: Role of Vitamin K Prophylactic Doses.

Ebid A, Abdeen H, Muhammed Maher R, Mohamed-Abdel-Motaleb S Hosp Pharm. 2024; 59(5):575-583.

PMID: 39318741 PMC: 11418688. DOI: 10.1177/00185787241238310.

A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation.

Liu J, Xiao J, Wu H, Ye J, Li Y, Zou B Int J Clin Pharm. 2024; 46(6):1492-1499.

PMID: 39269640 DOI: 10.1007/s11096-024-01796-w.

Development and internal validation of a model for predicting cefoperazone/sulbactam-associated coagulation disorders in Chinese inpatients.

Fu A, Ge F, Wang Y, Guo H, Zhu M, Li S BMC Pharmacol Toxicol. 2024; 25(1):41.

PMID: 38997770 PMC: 11241986. DOI: 10.1186/s40360-024-00761-7.

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder.

Miao W, Guo J, Cheng H, Zhao Q Infect Drug Resist. 2023; 16:6277-6284.

PMID: 37766881 PMC: 10520255. DOI: 10.2147/IDR.S429706.

References

Schentag J, Welage L, Williams J, Wilton J, ADELMAN M, RIGAN D . Kinetics and action of N-methylthiotetrazole in volunteers and patients. Population-based clinical comparisons of antibiotics with and without this moiety. Am J Surg. 1988; 155(5A):40-4. DOI: 10.1016/s0002-9610(88)80210-1. View

Mueller R, Green D, Phair J . Hypoprothrombinemia associated with cefoperazone therapy. South Med J. 1987; 80(11):1360-2. DOI: 10.1097/00007611-198711000-00007. View

Alagozlu H, Cindoruk M, Unal S . Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone. Clin Drug Investig. 2006; 26(8):481-4. DOI: 10.2165/00044011-200626080-00006. View

Schentag J, Welage L, Grasela T, ADELMAN M . Determinants of antibiotic-associated hypoprothrombinemia. Pharmacotherapy. 1987; 7(3):80-6. DOI: 10.1002/j.1875-9114.1987.tb03522.x. View

Koga H, Tomono K, Hirakata Y, Kohno S, Abe K, Kawamoto S . [Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase]. Jpn J Antibiot. 1996; 49(8):800-7. View

Shenkenberg T, Mackowiak P, Smith J . Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure. South Med J. 1985; 78(4):488-9. DOI: 10.1097/00007611-198504000-00035. View

Weitekamp M, Caputo G, Aber R . The effects of latamoxef, cefotaxime, and cefoperazone on platelet function and coagulation in normal volunteers. J Antimicrob Chemother. 1985; 16(1):95-101. DOI: 10.1093/jac/16.1.95. View

Ozen I, Moralioglu S, Karabulut R, Bagbanci B, Turkyilmaz Z, Demirogullari B . Cefoperazone induced gastro-intestinal haemorrhage. A case report. Acta Chir Belg. 2009; 108(6):777-8. DOI: 10.1080/00015458.2008.11680339. View

Schafer H, Naber K, Adam D . [Hemostasis disturbance caused by cephalosporins with an N-methylthiotetrazole side chain. A randomized pilot study]. Arzneimittelforschung. 1989; 39(9):1156-62. View

10.

Strom B, Schinnar R, Gibson G, Brennan P, Berlin J . Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. 2004; 8(2):81-94. DOI: 10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G. View

11.

Royer J, Freysz M, Sgro C, Dupont G, Honnart D . [Prolonged bleeding time in 2 patients with acute renal insufficiency during treatment with cefoperazone (2nd generation cephalosporin)]. Therapie. 1988; 43(6):485-8. View

12.

Cohen M, Washton H, Barranco S . Multicenter clinical trial of cefoperazone sodium in the United States. Am J Med. 1984; 77(1B):35-41. DOI: 10.1016/s0002-9343(84)80094-7. View

13.

Cristiano P . Hypoprothrombinemia associated with cefoperazone treatment. Drug Intell Clin Pharm. 1984; 18(4):314-6. DOI: 10.1177/106002808401800410. View

14.

Xin X, Jian L, Xia X, Jia B, Huang W, Li C . A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections. Ann Clin Microbiol Antimicrob. 2013; 12:38. PMC: 4029302. DOI: 10.1186/1476-0711-12-38. View

15.

Freedy Jr H, Cetnarowski A, Lumish R, Schafer F . Cefoperazone-induced coagulopathy. Drug Intell Clin Pharm. 1986; 20(4):281-3. DOI: 10.1177/106002808602000413. View

16.

Winston D, Ho W, Bruckner D, Champlin R . Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991; 115(11):849-59. DOI: 10.7326/0003-4819-115-11-849. View

17.

Narumi S, Sasaki M, Okudera D, Tann E, Konn M . Postoperative abnormal prothrombinemia in patients with cefoperazone: report of two cases. Surg Today. 1998; 28(2):227-30. DOI: 10.1007/s005950050113. View

18.

Pegram P, Phair J, McMahan R, Murphy R, Gordon L, Washton H . Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. J Antimicrob Chemother. 1989; 24(4):591-604. DOI: 10.1093/jac/24.4.591. View

19.

Jones P, Bodey G, Rolston K, Fainstein V, Riccardi S . Cefoperazone plus mezlocillin for empiric therapy of febrile cancer patients. Am J Med. 1988; 85(1A):3-8. DOI: 10.1016/0002-9343(88)90168-4. View

20.

Mortimer J, Miller S, Black D, Kwok K, KIRBY W . Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Am J Med. 1988; 85(1A):17-20. DOI: 10.1016/0002-9343(88)90170-2. View